Last reviewed · How we verify
NCT04616235
Acute Exercise and NK Cell Regulation in Tissue and Circulation After IL-6R Blockade
NA trial testing Tocilizumab Injectable Product in Interleukin-6 Inhibition in 30 participants. Completed in 4 October 2021.
4 October 2021
Quick facts
| Lead sponsor | Rigshospitalet, Denmark |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | basic science |
| Enrollment | 30 |
| Start date | 15 March 2021 |
| Primary completion | 4 October 2021 |
| Estimated completion | 4 October 2021 |
| Sites | 1 location across Denmark |
Drugs / interventions tested
- Tocilizumab Injectable Product — full drug profile →
- Saline 0.9% 100 ml NaCl 0.9% will be infused over 1 hour
Conditions studied
- Interleukin-6 Inhibition — all drugs for Interleukin-6 Inhibition →
- Physical Stress — all drugs for Physical Stress →
- Appetitive Behavior — all drugs for Appetitive Behavior →
Sponsor
Rigshospitalet, Denmark
Who can join
Adults 18 to 40, male only, with Interleukin-6 Inhibition or Physical Stress. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study is a randomized controlled trial studying the acute effect of intense aerobic exercise upon NK (Natural Killer) cell activation and appetite-regulation in human participants with or without concommitant IL-6R receptor blockade (Tocilizumab)
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Sympathetic nerve-adipocyte interactions in response to acute stress.
Santos GSP, Costa AC, Picoli CC, Rocha BGS, et al · · 2022 · cited 8× · PMID 34735579 · DOI 10.1007/s00109-021-02157-0
Verify or expand the search:
- PubMed search for NCT04616235
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Tocilizumab Injectable Product
Trials testing the same drug.
- NCT05067348 — Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis · Phase 2 · recruiting
Other Rigshospitalet, Denmark trials
Trials by the same sponsor.
- NCT07401368 — Clinicians' Trust in AI-Based Fetal Growth Estimates · NA · not yet recruiting
- NCT07442357 — The Per-procedural Antibiotic Prophylaxis in Patients Undergoing Transcatheter Aortic Valve Implantation Trial · NA · not yet recruiting
- NCT07528729 — Alcohol as a Modifiable Risk Factor for Atrial Fibrillation · NA · not yet recruiting
- NCT07511439 — Reversible Effects of Oral Contraceptive Removal on Serotonergic Neurotransmission · Phase 4 · not yet recruiting
- NCT07467187 — Invasive Home Ventilation in Denmark · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04616235 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Rigshospitalet, Denmark
- Last refreshed: 22 August 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04616235.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing